BRAINSTORM CELL THERAPEUTICS INC.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
BCLI$0.97+1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| | | | | | | |
|---|---|---|---|---|---|---|
| · · | ||||||
| · · December 31, | ||||||
| · · 2025 · · 2024 | ||||||
| · · U.S. $ in thousands | ||||||
| Cash flows from operating activities: · · · · | ||||||
| | | | | | | |
| Net loss | | $(10,307) | | $(11,623) | ||
| | | | | | | |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | ||
| Depreciation | | 199 | | 240 | ||
| Stock-based compensation related to options granted to employees and directors | | 1,520 | | 750 | ||
| Change in operating lease liability, net | | 87 | | 54 | ||
| Decrease (increase) in prepaid expenses and other accounts receivable | | | (83) | | | 401 |
| Increase (decrease) in trade payables | | 987 | | 1,126 | ||
| Increase in accrued expense | | | 85 | | | — |
| Gain on change in fair value of warrants (Note 7) | | (179) | | (147) | ||
| Increase (decrease) in employees related liability and accrued expenses | | 716 | | | 106 | |
| Total net cash used in operating activities | | $(6,975) | | $(9,093) | ||
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year ended | ||||||
| · · December 31, | ||||||
| · · 2025 · · 2024 | ||||||
| | | U.S. $ in thousands | ||||
| Cash flows from investing activities: | | | | | | |
| | | | | | | |
| Purchase of property and equipment | | | — | | | 12 |
| Changes in short-term deposit | | | — | | | — |
| Total net cash provided by investing activities | | $— | | $12 | ||
| | | | | | | |
| Cash flows from financing activities: | | | | | | |
| Proceeds from issuance of shares in at-the-market (ATM) offering (Note 8) | | | 4,347 | | | 4,323 |
| Proceeds from Issuance of shares for private placement (Note 8) (*) | | | — | | | 3,644 |
| Proceeds from short-term loans (Note 11) | | | 582 | | | — |
| Proceeds from warrants issuance (Note 7)(*) | | | 1,501 | | | — |
| Debt-for-Equity Swap | | | 450 | | | — |
| Total net cash provided by financing activities | | $6,880 | | $7,967 | ||
| Decrease in cash and cash equivalents | | | (95) | | | (1,114) |
| | | | | | | |
| Cash, cash equivalents and restricted cash at the beginning of the period | | $371 | | $1,485 | ||
| | | | | | | |
| Cash, cash equivalents and restricted cash at end of the period | | $276 | | $371 | ||
**(*)**Presented after neutralizing costs of issuance.
| | | | | |
|---|---|---|---|---|
| · · Year ended | ||||
| · · December 31, | ||||
| | | 2025 | | 2024 |
| Non-Cash Activities: · · USD in thousands | ||||
| Reclassifying the warrants liabilities to equity (Note 8) | | 268 | | — |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.